A comprehensive understanding of the mechanistic differences among CXCL12/CXCR4 modulators—including classical antagonists, pathway-specific inhibitors, and bioactive natural compounds—is therefore essential for designing therapies aligned with distinct stages of ALI/ARDS pathogenesis. This evidence concerns the gene CXCR4 and acute respiratory distress syndrome.